Skip Navigation LinksHome   |   About CIBMTR   |   What We Do   |   SCTOD
  • Print
  • Share

Stem Cell Therapeutic Outcomes Database (SCTOD)

CIBMTR holds the contract for the Stem Cell Therapeutic Outcomes Database (SCTOD), awarded by the Health Resources and Services Administration of the U.S. Department of Health and Human Services.

Understanding the SCTOD

The SCTOD is part of the C.W. Bill Young Cell Transplantation Program (Program), authorized by the Stem Cell Therapeutic and Research Act of 2005 (Public Law 109-129) and reauthorized by the Stem Cell Therapeutic and Research Reauthorization Act of 2010 (Public Law 111-264).

As the contract holder, the CIBMTR is charged with collecting data on all allogeneic (related and unrelated) hematopoietic cell transplantations (HCTs) performed in the United States, and on all HCTs done with products procured through the Program but performed outside of the United States.

The SCTOD database allows analysis of Program use, center-specific outcomes, size of donor registry and cord blood inventory, and patient access to HCT.

SCTOD builds on the foundation of the CIBMTR

Because of the collaboration and dedication of physicians and data managers at transplant centers, the field of transplantation already had in place a tremendous voluntary data submission mechanism. The SCTOD builds upon the existing CIBMTR infrastructure and expertise for data collection, management and analysis.

The data collected for the SCTOD represent a sub-set of the overall CIBMTR database, which also includes voluntarily submitted autologous transplantation data from U.S. CIBMTR centers, and autologous and allogeneic transplantation data from non-U.S. CIBMTR centers.

In managing the SCTOD, the CIBMTR collaborates with transplant centers to:

  • Develop data reporting requirements for allogeneic transplants in the United States
  • Manage a related donor-recipient research sample repository
  • Design and maintain systems to collect data and make it publicly available
  • Study center-specific outcomes
  • Collect data on novel therapeutic uses of hematopoietic stem cells

Learn more about the C.W. Bill Young Cell Transplantation Program at

Last Updated: 5/12/2015 11:36 AM